AUTOANTIBODIES have been demonstrated in patients with various malignant diseases, including breast cancer, but the reports have been somewhat conflicting. Whitehouse & Holborow (197 1) found that smooth-muscle antibody and antinuclear factor occurred more frequently in cancer patients. Similarly, Wasserman et at. (1975) found a raised incidence of smoothmuscle and antinuclear antibodies in breast-cancer patients, and 20% of all the cancer patients they studied had more than one antibody. These patients had a worse prognosis. Further studies have confirmed the raised incidence of antinuclear factor in malignant disease (Burnham, 1972; Zeromski et al., 1972) . However, Tannenberg et al. (1973) reported that the incidence of autoantibodies in cancer patients was less than in patients with non-malignant diseases and Mittra et al. (1976) found a similar incidence of thyroid antibodies in breast-cancer patients and healthy controls. They also found that the incidence of 6 other autoantibodies was not raised in breast-cancer patients.
In an attempt to clarify the situation, the incidence of autoantibodies in breast cancer has been examined further in patients with early breast cancer.
Patients
The patients form part of a unicentric randomized prospective clinical trial com- Accepted 16 June 1978 paring simple mastectomy alone with simple mastectomy plus radical radiotherapy as a treatment for early breast cancer (Turnbull et al., 1978) . Ninety-six patients were studied, of whom 46 received radiotherapy (DXT); the remaining 50 were closely observed (OB).
An axillary-lymphnode biopsy was routinely performed at operation. In addition, the patients were skin-tested preoperatively with 3 recall antigens (10 units of purified protein derivative, 0-02 ml of 0.5% Candida albicans (Bencard) and 10 units of Varidase (streptokinase/streptodornase). Fifty-one age-and sex-matched controls were taken from a hospital visitors' control panel.
Autoantibodies
Sera were obtained from the patients preoperatively, and 6 months later. All the tests were carried out on the patients and controls at the same time, the sera having been stored at -20TC. The same substrates and conjugates were used throughout.
The sera were diluted 1: 10 and tested by indirect immunofluorescence against unfixed sections of human thyroid, rat stomach, mouse stomach, rat kidney, rat liver and rat salivary gland, as previously described (Triger et at., 1976 ). The sera were tested using either a monovalent or a polyvalent antihuman-Ig antiserum, conjugated with fluorescein isothiocyanate, as appropriate.
Thyroglobulin antibodies and rheumatoid factor were detected by the tanned red cell method of Boyden (1951) and by haemagglutination (Ball, 1952) . 
Statistics
The Chi-square test with Yates' correction, the exact test or Student's t test were used as appropriate.
RESULTS
The incidence ofautoantibodies detected in the patients and controls is shown in Table I . There is no significant difference in the individual antibodies between the two groups. Eighty-eight patients showed no change in their autoimmunity profiles from the preoperative specimen to the 6-months postoperative specimen, and radical radiotherapy did not alter the incidence of autoantibodies. Minor insignificant changes occurred in the other 8 patients.
Autoantibodies occurred significantly more frequently in the breast-cancer patients than in controls (Table II) but the incidence of more than one antibody in any individual was not greater.
There were 60 patients whose sera contained one or more autoantibodies, and 36 in whom no autoantibodies were found. No ANA was found in the LN-group, but a total of 10 (24%) LN+ patients had ANA in their serum (P<0.001). Seven of these patients were positive for IgG ANA and 9 for IgM ANA. In the remaining 4 ANA+ patients lymphnode histology was not available. Sixteen patients did not react to any of the 3 recall antigens. The incidence of ANA in these patients was 31 % which was significantly greater than the 11% I incidence found in the skin-test-reactive patients (P<0-05). Eleven patients had either died or developed distant metastases within the first 12 months, but the incidence of autoantibodies in this group was comparable with that in the 85 patients who had no evidence of widespread dissemination at this time. DISCUSSION We have found that the incidence of individual autoantibodies in patients with early breast cancer is not significantly greater than in a control population. This finding is consistent with that of Mittra et al. (1976) . However, overall there is an increased incidence of autoantibodies in the cancer patients, with 63% giving positive results in one or more of the major antigen-antibody systems tested, compared with 47% in the control group. The incidence of more than one antibody in individual patients was not increased.
A striking difference was noted in the incidence of antinuclear antibody in patients with lymphnode metastases: 24% of patients who had developed spread to the axilla gave positive results, whereas no patient with a negative lymphnode biopsy had antinuclear antibody. This stagerelated difference might well account for the previous variations in incidence which have been reported in the literature.
The incidence of autoantibodies was not altered by surgery or radical radiotherapy. The preoperative autoimmune profiles were virtually identical with the 6-months postoperative results in both irradiated and observed patients.
Age did not appear to be a contributory factor. The mean age of patients showing one or more antibodies in their sera was the same as the mean age of those patients with no antibodies, and similar to the mean age of the controls. This finding is in agreement with that of Gray et al. (1975) , who reported that there was no age-related increase in incidence of autoantibodies in cancer patients.
Antinuclear antibody was present more frequently (31%) in anergic patients than in skin-test-reactive patients (11%). This would be expected if they both correlate with a state of immunodeficiency.
At 12 months there was no correlation between individual autoantibodies and clinical outcome. However, a stage-related increased incidence of ANA was noted, and since Stage II breast-cancer patients have a worse prognosis, a correlation may become apparent with longer follow-up.
In conclusion, this study has shown that the incidence of autoantibodies is increased in early breast cancer. Of particular interest is the fact that the presence of antinuclear antibody, previously reported in cancer patients, appears to be a stagerelated phenomenon. 
